Listing Category
Description
A single-arm, open-label, Phase 2 study evaluating A single-arm, open-label, Phase 2 study evaluating by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)